Maria Greenwald

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +16

Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Stanley Cohen, Robert M. Levy, Michael Keller et al. · Arthritis & Rheumatism · 1999 · 617 citations

Medicine, Orthopedic Surgery, Pharmacotherapy +17

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

Clifton O. Bingham, R. John Looney, Atul Deodhar et al. · Arthritis & Rheumatism · 2009 · 462 citations

Life Sciences, Immunology, Internal Medicine +17

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

Maxime Dougados, Désirée van der Heijde, Ying‐Chou Chen et al. · Annals of the Rheumatic Diseases · 2016 · 399 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

Philip J. Mease, Mark C. Genovese, Maria Greenwald et al. · New England Journal of Medicine · 2014 · 392 citations · Full text

Medicine, Immunology, Pharmacotherapy +16